Syngene International Limited — Board Meeting, 23-07-2025: Outcome of Board Meeting

Syngene International's board has approved the financial results for the quarter ended June 30, 2025. Consolidated revenue from operations reached Rs 874.5 Cr, with a net profit of Rs 86.7 Cr. The board also proposed a final dividend of Rs 1.25 per share, pending shareholder approval.

Strategically, Syngene expanded its global footprint by acquiring a biologics site in the USA, boosting its large molecule manufacturing capabilities. Furthermore, its Bangalore biologics facility (from Stelis Biopharma) secured licenses for a drug substance line and bonded warehouse, making it fully operational and ready for enhanced production.